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ABSTRACT  
 
OBJECTIVE: 
To determine the level of agreement of disease flare severity (distinguishing severe, moderate and 
mild flare and persistent disease activity) in a large paper patient exercise involving 988 individual 
cases of systemic lupus erythematosus.  
 
METHODS: 
988 individual lupus case histories were assessed by three individual physicians. Complete 
agreement about the degree of flare (or persistent disease activity) was obtained in 451 cases (46%) 
and these provided the reference standard for the second part of the study. This component utilised 
three flare activity instruments (BILAG 2004, SELENA flare index (SFI) and the revised SELENA flare 
index (rSFI)). The 451 patient case histories were distributed to 18 pairs of physicians being carefully 
randomised in a manner designed to ensure a fair case mix and equal distribution of flare according 
to severity.  
 
RESULTS: 
The three physician assessment of flare matched the level of flare using the three indices thus 67% 
for BILAG 2004, 72% for SFI and 70% for rSFI. The corresponding weighted kappas for each 
instrument were 0.82, 0.59 and 0.74 respectively. We undertook a detailed analysis of the 
discrepant cases and several factors emerged including a tendency to score moderate flares as 
severe and persistent activity as flare especially when the SFI and rSFI instruments were used. 
Overscoring was also driven by scoring treatment change as flare even if there were no new or 
worsening clinical features.  
 
CONCLUSIONS: 
Given the complexity of assessing lupus flare, we were encouraged by the overall results reported. 
However the problem of capturing lupus flare accurately is not completely solved.  
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SIGNIFICANCE AND INNOVATION  
 
This study addresses the ongoing dilemma of how best to capture flare in patients with SLE. In our 
previous attempt to do this using 16 “live” patients we could only assess a modest number of lupus 
manifestations. In the current study we have utilised nearly 1,000 paper-based case histories in 
order to determine the capacity of three flare activity instruments (BILAG 2004, SELENA flare index 
(SFI) and the revised SELENA flare index (rSFI) to capture flare. We show that all three instruments 
are able to do this in many cases but there is an ongoing need to do even better.  
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Introduction: 
In the past 30 years methods of assessing disease activity in patients with lupus have improved 
considerably. Both global score systems, such as the Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI), Systemic Lupus Activity Measures (SLAM) and the European Community Lupus 
Activity Measure (ECLAM), and the British Isles Lupus Assessment Group (BILAG) system, which 
focuses on individual organs or systems, have emerged as viable and effective activity assessment 
instruments. SLEDAI and BILAG have been revised to SLEDAI-2K [1] and BILAG-2004 index [2], 
respectively, with large-scale studies undertaken to demonstrate their validity, reliability and 
sensitivity to change [reviewed in 3]. 
Although both the SLEDAI and BILAG activity assessments are widely used in large-scale international 
trials of new biologic drugs [e.g. 4, 5, 6], there are few data assessing their usefulness in determining 
clinical flares in patients with lupus [7]. The Lupus Foundation of America held two investigator 
meetings in 2007 and 2008 which sought to agree the definition of flare in lupus patients [8]. They 
concluded that flare is  ‘a measurable increase in disease activity in one or more organ systems 
involving new or worse clinical signs and symptoms and/or laboratory measurements. It must be 
considered clinically significant by the assessor and usually there will be at least consideration of 
initiation or increase in treatment.’ 
A particular challenge in patients with lupus has been distinguishing mild, moderate and severe 
flares and distinguishing them from ‘ongoing’, persistent disease. This problem is in part related to 
difficulties in agreeing what constitutes such flares in different organs and systems, but also because 
when a patient is flaring there may be a difference in the degree of flare in different organs or 
systems.  
A live patient study of 16 flaring patients with lupus [9] took place in London in May 2009. In this 
study three assessment instruments were utilised to assess flare. One was based on the BILAG 2004, 
a second was the classic SELENA Flare Index (SFI), and the third was the revised SELENA flare index 
(rSFI: an organ-based system that is based on, but not directly linked to, the SLEDAI). 
In that live patient study [9], a panel of rheumatologists [one of whom was the patient’s own 
clinician] determined the severity of flare in each patient and then different individual 
rheumatologists assessed each patient for flare with all 3 instruments. Intra-class correlation co-
efficients (with 95% confidence interval) were calculated to indicate a measure of internal reliability. 
The results were 0.54 (0.32 to 0.78) for the BILAG 2004 flare assessment compared with 0.21 (0.08 
to 0.48) for the revised SELENA flare instrument and 0.18 (0.06 to 0.45) for the Physicians Global 
Assessment of flare. Severe flare was associated with good agreement between the three 
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instruments, but the mild to moderate flares were less consistent. Although assessing real patients 
offers the tangible advantage of testing potential flare instruments in a more realistic way, obviously 
the numbers of patients (and their clinical problems) that can be studied at any given time is 
restricted. In order to expand our experience of flare assessment in lupus, we have now undertaken 
a major paper patient-based exercise which has allowed us to review a much broader array of lupus 
symptomatology and to utilize a larger number of assessors to determine flare status using 
individual instruments on paper case reports based on real cases. 
The objective of this study was to determine the level of agreement of flare severity 
(severe/moderate/mild/none: ie persistent disease activity) identified in paper patient cases using 
three flare instruments and physician defined flares determined by a panel of three physicians.  
 
Methods: 
Generation of Clinical Case scenarios 
Participating physicians were given a standardised report form to complete which included four 
sections: previous lupus assessment and treatment; details of assessment at visit being evaluated for 
flare; results of relevant investigations (blood, urine, imaging, biopsies etc) influencing this 
assessment; treatment changes at this visit. 
Thirty physicians submitted a total of 988 anonymous individual paper case reports based on the 
medical records of their patients. Each patient met the revised classification criteria of the American 
College of Rheumatology [10] and/or the 2012 Systemic Lupus International Collaborating Clinics 
(SLICC) criteria [11]. The submitting physician was also asked to provide their assessment of the flare 
category for the paper patient case (severe, moderate or mild flare or “persistent/ongoing” disease) 
and to submit roughly equal numbers of each category. The actual distribution of paper patient 
cases received was: 25% severe, 28% moderate, 22% mild, 25% persistent disease activity without 
flare. 
Each patient case report was then assessed for flare category by a further two reviewing physicians 
who did not know the patient. The cases were allocated at random and randomisation was designed 
to ensure an equal distribution of submitted category type and to ensure no physician reviewed 
their own submitted cases or the same case twice. The flare category assigned by each of the three 
physicians (one submitting and two reviewing) was then compared. 
All three physicians agreed on the flare category in 451 cases (46%). We refer to this flare 
assessment as three physician consensus (TPC) and these are the cases that were carried forward to 
be assessed by the flare instruments in the study. The TPC result for each case formed the reference 
standard for our later analyses. Flare category distribution in these cases was: 32% severe, 21% 
moderate, 24% mild, 23% persistent disease not flare. 
TPC was not achieved in 535 cases (54%). In 376 cases (38%) there was partial agreement i.e. any 
two physicians agreed with each other (but not with the third physician), in 41 cases (4%) there was 
no agreement between any physician i.e. all three physicians recorded different levels of flare or 
persistent activity for these cases.  One or both of the reviewing physicians rejected 118 cases (12%) 
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as “unable to code” on the information provided. Two of us (DAI and CG) reviewed these cases to 
assess whether there were any particular reasons why it has been hard to achieve TPC. 
The 451 TPC patient case histories were carefully reviewed by one of us (DAI) and assigned into one 
of eight clinical groups thus: those with musculo-skeletal and/or skin disease only; joint and/or skin 
and renal disease; mainly serositis; mainly renal; mainly gastro-intestinal; mainly CNS; joints and/or 
skin plus serositis, and other which included those that were predominantly haematological and/or 
constitutional or other combinations. Two cases were excluded from further assessment as one was 
found to be a duplicate and the other case report form had been completed incorrectly. 
Assessment of TPC paper case reports using standard instruments 
The 451 TPC patient case histories were distributed to 18 pairs of physicians. The cases were 
randomised in a manner designed to ensure each pair received a fair case-mix, based on the clinical 
groups set out above and an equal distribution of flare by category type. 
The 18 pairs of rheumatologists were each asked to agree on the level of flare in, between 20 and 26 
individual paper cases. Each pair was assigned to use one of the three flare assessment instruments, 
these were the BILAG-2004 index [12] (6 pairs) or the SFI [13] (6 pairs) and the rSFI [9] (6 pairs). Full 
details of the flare instruments are shown as supplementary material. Analyses were done both 
including and excluding flare defined only by treatment change. 
The pairs of rheumatologists were asked to undertake the assessments of flare using the instrument 
assigned to them separately and then to confer to achieve full agreement on the score and level of 
flare using that instrument or to record persistent activity without flare. 
Statistical methods used: 
For each flare instrument, the level of flare agreed by the assessing pair of physicians was compared 
to the TPC flare assessment (the reference standard) for each case.  The level of agreement between 
the flare instrument used and the TPC flare assessment was determined in two ways; firstly by 
simply calculating the percentage of cases where there was complete agreement and secondly by 
calculating a weighted kappa with quadratic weights (equivalent to an intraclass correlation 
coefficient). The weighted Kappa give weights to the frequencies in each cell of the table according 
to their distance from the diagonal, thus allowing different levels of agreement to contribute.  
 
Results: 
 
 
Of the 451 cases 7 were rejected by the pairs of physicians for providing too little information to 
score using the assigned flare instrument (6 cases for BILAG 2004 index and 1 for SELENA-SLEDAI 
flare instrument). 
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Tables 1, 2 and 3 show the results for each type of flare assessed by the BILAG 2004, SFI and the rSFI 
respectively and compared with the TPC level of flare (note that different clinical cases were 
assessed by each instrument so the indices cannot be directly compared with each other). 
For all three flare instruments, agreement on the level of flare as assessed by each instrument and 
by the TPC assessment occurred in a similar proportion of cases. The level of flare matched the TPC 
assessment of flare in the individual cases in a similar proportion of times using the original versions 
of these instruments: 67% for BILAG-2004 index, 72% for SFI and 70% for rSFI. The corresponding 
weighted kappas for each instrument were BILAG 2004 index 0.82, SFI instrument 0.59, rSFI 0.74.  
An analysis of the discrepant cases where there was a difference in the assessment of flare between 
the TPC and the flare instrument was undertaken. There was a consistent pattern across all three 
instruments of a tendency to score moderate flares as severe and scoring some of the no 
flare/persistent activity cases as flare when the SFI and rSFI instruments were used. Close 
examination of the data in tables 2a and 3a suggested that this over-scoring was driven by scoring 
treatment change as flare even if there were no new or worsening clinical features. Tables 2b and 3b 
show the adjusted results.  Only one out of the 17 cases assessed by the SELENA-SLEDAI flare 
instrument as a flare but as no flare by TPC had increased lupus activity without treatment change 
and in 2 cases the treatment change led to a higher level of flare than the clinical features alone 
would have scored. With the rSFI instrument only 1 out of 5 cases recorded as severe SELENA flare 
but no flare by TPC had clinical features of flare, the others were due to treatment change alone.  In 
one case there was mild flare by TPC but severe SELENA flare due to treatment change.  Excluding 
flare defined primarily by treatment change when assessing flares (tables 2b and 3 b) using the SFI 
and rSFI led to an increase in the proportion of cases with agreement between the TPC and the 
instruments to 79% and 78% respectively and improved the weighted kappa scores to 0.82 and 0.73 
respectively.* 
For the cases assessed by the BILAG 2004 index in Table 1, there were 2 cases with severe BILAG 
flare that were appropriately scored and it was not clear why the TPC assessment was of no flare. 
For the 2 cases with severe flare by TPC assessed as mild by the BILAG assessors, review suggested 
that they had not been scored correctly and that the criteria for severe flare (BILAG A scores) were 
present in both cases. There were also 2 out of 4 cases recorded by TPC as severe flare with a 
moderate flare reported by the BILAG assessors but the criteria for severe flare were present. In 3 
out of 4 of these cases scored at a lower level by the BILAG assessors, neurological items were 
underscored as B instead of A for reasons that are not clear. The patients with severe flares recorded 
by BILAG, but moderate flares by TPC, were correctly scored for BILAG in 9 out of 11 cases and were 
mostly mucocutaneous or musculoskeletal flares (8 out of 11 cases , with 2 cardio-respiratory flares 
and one renal flare). 
Discussion: 
This paper-patient exercise has allowed the assessment of a much wider range of clinical problems 
compared to the previous live patient exercise (9). By utilizing over 40 rheumatologists with a major 
interest in SLE we were able to collect a large number of cases for flare assessment and involved a 
much larger number of assessors. The disposition of case review assignments was arranged to 
ensure that a similar range of cases was reviewed by all participating physicians. In the first part of 
the study, the 988 case histories were reviewed independently by three rheumatologists and full 
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agreement as to whether the patient was suffering a mild, moderate or severe flare or experiencing 
persistent/ongoing disease was achieved in 451 cases (46%). Review of discrepant cases suggested 
that there were some errors in the scoring of the BILAG 2004 index without which the levels of 
agreement would have been higher, emphasising the importance of training in the use of the 
glossary and the scoring manual. Although there was some evidence that single system severe A 
level flares by BILAG 2004 index in mucocutaneous and musculoskeletal systems were sometimes 
perceived to be moderate level flares by the TPC, the case descriptions varied in the amount of 
detail provided and it is difficult to attach much significance  to the small number of cases that this 
applied to given that the presence of  a significant flare was clear to all assessors. 
 
The case histories with full agreement were then utilized, in effect, as our ‘gold standard’ cases. The 
three lupus flare instruments ie BILAG-2004, SFI index and rSFI were used to assess flare in different 
cases in the second part of the study and performed equally well, particularly if treatment change 
was excluded as a component of the flare score. In practice, the scores from the pairs of 
rheumatologists that completed the BILAG-2004 or SFI index or the rSFI index demonstrated a high 
level of agreement overall with the pre-determined TPC level of flare, and for the specific types of 
flare, especially for severe flare (levels of agreement of 85% or higher). Distinguishing mild and 
moderate flares from persistent activity/no flare and severe flare as assessed by the TPC method 
was more consistently achieved when the SFI and rSFI instruments were used without the rules that 
required all treatment change to determine flare. This issue has previously been reported in a 
smaller retrospective real patient cohort study [14]. It is apparent that treatment change by itself 
will quite frequently fail to indicate worsening disease as adverse events, or treatment intolerance, 
may complicate matters. As a ‘treat to target’ philosophy gains traction in the management of SLE 
this increases the likelihood that treatment change will be widely used to define flare when it may 
simply reflect ‘fine tuning’ of managing persistent disease. Nevertheless an ‘intent to treat principle’ 
remains useful to reflect broadly clinically important levels of disease activity.  
 
It should be noted that a  few  cases (seven) were not scored but were included in the analysis 
despite insufficient information, predominately (6/7 cases) those for BILAG flare assessment as this 
is more demanding in terms of the information required for accurate and comprehensive 
completion of case report forms. Where there was initial discord in flare scoring for the other cases 
reported, the pairs reported that by discussion (usually via telephone conference) agreement could 
be reached relatively easily in the vast majority of cases even though the quality of the case 
scenarios was rather variable. The pairs of assessors only used one instrument and each of the three 
of types of flare instrument were not used on the same cases by the same people.  
In 535 (54%) of the 988 cases originally submitted for flare assessment, consensus on the level of 
flare without using a flare instrument could not be agreed by three physicians.  Although in some 
cases there was insufficient information for some of the physicians to rate the case, for example 
because the severity was not clear enough or the time of onset of the deterioration was not 
adequately defined (to distinguish flare from persistent activity or damage), there were other cases 
where consensus agreement could not be achieved despite reasonable scenarios . These were 
mostly those cases with multiple systems involved, presumably because different physicians ranked 
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the components differently, particularly if some systems changed severity to different extents or not 
consistently with some symptoms worse and others stable or improved. This is reminiscent of a 
problem noted previously in a study evaluating responsiveness using BILAG and SLEDAI compared 
with a physician visual analogue scale [15] and emphasises the advantage in obtaining consistency of 
scoring in flare instruments with defined glossaries rather than relying solely on physician opinion.  
However, limitations of disease definitions that rely on predefined thresholds of severity cannot be 
excluded.  
Although the capacity of paper patient exercises greatly increases the range of possible 
combinations of lupus clinical features for assessment in studies of this kind, nothing captures the 
dilemma of lupus assessment as much as a real patient in front of a clinician. Nevertheless the 
practicalities of getting large numbers of patients who are actually flaring into a clinical assessment 
study of the type that we reported previously (9) are considerable. In retrospect we would probably 
have obtained greater agreement amongst the raters/assessors and a larger panel of cases for flare 
assessment with much tighter requirements/standardization for the writing of the case histories. An 
advantage of the case histories is that they were devised from real clinic patients. We are aware that 
there may have been biases in that some of the assessors may have been more or less experienced 
in the assessment instruments used.  
 
It is notable that it is not just in SLE that challenges are evident in attempting to capture flare 
adequately, and distinguish it from ongoing disease. Thus the OMERACT RA Flare Group have been 
involved in similar studies for several years (16). Their work is ongoing and the fact that they are 
dealing with a single organ/system highlights the added complexity when dealing with lupus. 
 
Although it would not be true to say that the problem of capturing flare accurately in patients with 
lupus is ended, the relatively high levels of agreement obtained with the flare instruments and 
weighted kappas  ranging from 0.59 (SFI instrument with treatment) to 0.82 ( for SELENA without 
treatment and BILAG-2004) was encouraging especially given some problems with inadequate 
histories and the great diversity of rheumatologists from many different countries involved in the 
study. All of the instruments used in this study have construct and content validity based on their 
use with these paper patient scenarios. The choice of instrument to be used in future flare studies 
will depend on the types of patients to be assessed, the need to distinguish different types of flares 
and the training and experience of the likely investigators. 
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Table 1: Number of cases by BILAG 2004 flare assessment and % agreement with TPC flare 
assessment 
 TPC  flare assessment  
 
Total No flare Mild flare 
Moderate 
flare Severe flare 
BILAG flare 
assessment 
n (% agreement) 
No flare 27 (75) 11 (31) 2 (7) 0 40 (27) 
Mild flare 4 (11) 23 (64) 6 (21) 2 (4) 35 (24) 
Moderate flare 1 (3) 0 9 (31) 4 (8) 14 (9) 
Severe flare 2 (6) 0 11 (38) 41 (85) 54 (36) 
Insufficient information 2 (6) 2 (6) 1 (3) 1 (2) 6 (4) 
Total 36 36 29 48 149 
TPC : three physician consensus 
Table 2a: Number of cases by SELENA – SLEDAI flare instrument assessment and % agreement with 
TPC flare assessment 
 TPC  flare assessment 
 
Total No flare 
Mild/moderate flare 
(combined) Severe flare 
SELENA flare 
assessment 
n (% agreement) 
No flare 17 (49) 5 (7) 0 22 (15) 
Mild/moderate flare 8 (23) 49 (67) 0 57 (38) 
Severe flare 9 (26) 19 (26) 44 (100) 72 (47) 
Insufficient information 1 (3) 0 0 1 
Total 35 73 44 152 
TPC : three physician consensus 
 
Table 2b: Number of cases by SELENA – SLEDAI flare assessment and % agreement with TPC flare 
assessment – excluding flare defined by treatment change 
 TPC flare assessment 
 
Total No flare 
Mild/moderate flare 
(combined) Severe flare 
SELENAFlare 
Index without 
treatment flare 
assessment 
n (% agreement) 
No flare 22 (63) 10 (14) 0 32 (21) 
Mild/moderate flare 8 (23) 53 (73) 0 61 (40) 
Severe flare 4 (11) 10 (14) 44 (100) 58 (38) 
Insufficient information 1 (3) 0 0 1 
Total 35 73 44 152 
TPC : three physician consensus 
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Table 3a: Number of cases by SELENA flare assessment and % agreement with TPC flare assessment 
 TPC flare assessment  
 
Total No flare Mild flare 
Moderate 
flare Severe flare 
Revised SELENA  
flare 
assessment 
n (% agreement) 
No flare 18 (58) 0 0 0 18 (12) 
Mild flare 4 (13) 16 (44) 0 0 20 (13) 
Moderate flare 4 (13) 19 (53) 19 (63) 1 (2) 43 (29) 
Severe flare 5 (16) 1 (3) 11 (37) 52 (98) 69 (46) 
Insufficient information 0 0 0 0 0 
Total 31 36 30 53 150 
TPC : three physician consensus 
 
Table 3b: Number of cases by SELENA flare assessment and % agreement with TPC flare assessment- 
excluding flare defined by treatment change 
 TPC flare assessment  
 
Total No flare Mild flare 
Moderate 
flare Severe flare 
Revised SELENA  
flare 
assessment 
n (% agreement) 
No flare 23 (74) 0 0 2 (4) 25 (17) 
Mild flare 4 (13) 25 (69) 5 (16.7) 1 2) 35 (23) 
Moderate flare 3 (10) 11 (31) 23 (77) 3 (6) 40 (27) 
Severe flare 1 (3) 0 (0) 2 (7) 47 (89) 50 (33) 
Insufficient information 0 0 0 0 0 
Total 31 36 30 53 150 
TPC : three physician consensus 
 
 
 
